Nutriband Inc. (NTRB)

3.3600 -0.0400 (-1.18%) At close: 04:00PM EDT

Nutriband Inc.

121 South Orange Avenue
Suite 1500
Orlando, FL 32801
United States
407 377 6695
https://nutriband.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Serguei Melnik	Founder, President, Company Secretary & Executive Chairman of the Board	175k	N/A	1974
Mr. Gareth Sheridan	Founder, CEO & Director	175k	N/A	1990
Mr. Gerald Goodman	CFO & Chief Accounting Officer	140k	N/A	1948
Dr. Alan Smith Ph.D.	COO & President of 4P Therapeutics	159k	N/A	1966
Dr. Jeffrey Patrick Pharm.D.	Chief Scientific Officer	N/A	N/A	1970
Mr. Michael Myer	President of Pocono Pharmaceutical	40.6k	N/A	1985
Mr. Tyler Overk	Head of Active Intelligence	N/A	N/A	1984

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Corporate governance

Nutriband Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.